Work

NCI 10066: A phase 1 / 2 study of olaparib in combination with ramucirumab in metastatic gastric and gastroesophageal junction (GEJ) adenocarcinoma.

Year: 2018

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2018.36.15_suppl.tps4137

Authors: Michael Cecchini, Patricia LoRusso, Yu Shyr, S. Percy Ivy, Jeffrey Sklar, Kirsten Dooley, Jill Lacy

Institutions: Yale University, Yale Cancer Center, Vanderbilt University, Vanderbilt-Ingram Cancer Center, National Institutes of Health, National Cancer Institute, Smilow Cancer Hospital

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2891326852

Cites:

Cited by: 3

Related to: 10